Andrew Hopkins, Exscientia CEO

The cash won't stop for Ex­sci­en­tia as it makes a $300M+ Nas­daq de­but

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

An AI biotech with lit­tle hu­man da­ta — but lots of hype — is once again drown­ing in cash.

Ex­sci­en­tia priced its IPO late Thurs­day evening, an­nounc­ing it pulled in $304.7 mil­lion with the raise. The pub­lic de­but marks Ex­sci­en­tia’s third nine-fig­ure raise of the year, af­ter the biotech ex­pand­ed its Se­ries C to $100 mil­lion in March and raised more than half a bil­lion dol­lars in a pair of fi­nanc­ings in April. Ex­sci­en­tia shares will be­gin trad­ing Fri­day at $22 apiece un­der the tick­er $EX­AI.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.